In recent years, multiple randomised clinical trials have reported that sodium−glucose cotransporter 2 (SGLT2) inhibitors significantly reduce hospitalisations for acute decompensated HF in patients with type 2 diabetes (T2D) [3,4,5,6,7]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.